Global mobile CGT Opportunity to expand partnerships around mobile cell and gene therapy manufacturing platforms, leveraging Boston Labs' recent collaboration with Germfree Laboratories to offer on-site, at-point-of-care solutions in additional regions.

End-to-end supply Sell integrated end-to-end clinical trial supply chain and logistics services, highlighting rapid packaging, minimized queues, and risk reduction as a differentiator for sponsors seeking faster study startup and more reliable study execution.

Technology leverage Position Boston Labs as a tech-enabled partner using cloud, collaboration tools, and AI capabilities (OpenAI, Google Cloud, WordPress workflows) to optimize trial operations, data visibility, and forecasting for stakeholders.

Scale with capacity Target mid-market and growing CROs/biotech firms with revenue in the lower mid multiple billions range by emphasizing scalable infrastructure and the potential to support global trial rollouts as they expand.

Evidence of expansion Highlight recent product and service expansions, such as the Micron 5400 PRO SSD introduction and mobile CGT platform launches, to demonstrate capability and commitment to advancing trial efficiency and technology-driven logistics.